Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic
Ludger Klimek, Oliver Pfaar, Margitta Worm, et al.
Allergologie select (2020) Vol. 4, Iss. 01, pp. 53-68
Open Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status
Thomas B. Casale, Ana M. Giménez‐Arnau, Jonathan A. Bernstein, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 11, pp. 2573-2588
Open Access | Times Cited: 17
Anti-IL5 Drugs in COVID-19 Patients: Role of Eosinophils in SARS-CoV-2-Induced Immunopathology
Daniele Pala, Marco Pistis
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 36
COVID-19 vaccination of patients with allergies and type-2 inflammation with concurrent antibody therapy (biologicals) – A Position Paper of the German Society of Allergology and Clinical Immunology (DGAKI) and the German Society for Applied Allergo
Oliver Pfaar, Ludger Klimek, Eckard Hamelmann, et al.
Allergologie select (2021) Vol. 5, Iss. 01, pp. 140-147
Open Access | Times Cited: 33
How Infection and Vaccination Are Linked to Acute and Chronic Urticaria: A Special Focus on COVID-19
Emek Kocatürk, Melba Muñoz, Daniel Elieh Ali Komi, et al.
Viruses (2023) Vol. 15, Iss. 7, pp. 1585-1585
Open Access | Times Cited: 16
Management of Allergic Diseases During COVID-19 Outbreak
Adriana Izquierdo-Domínguez, María Jesús Rojas‐Lechuga, Isam Alobid
Current Allergy and Asthma Reports (2021) Vol. 21, Iss. 2
Open Access | Times Cited: 26
Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome
Dimitri Poddighe, Elena Kovzel
Journal of Inflammation Research (2021) Vol. Volume 14, pp. 6845-6853
Open Access | Times Cited: 23
Severe acute respiratory syndrome coronavirus 2 infection in those on mepolizumab therapy
Adnan Azim, Laura Pini, Zeeshan Khakwani, et al.
Annals of Allergy Asthma & Immunology (2021) Vol. 126, Iss. 4, pp. 438-440
Open Access | Times Cited: 18
Biologics for atopic diseases: Indication, side effect management, and new developments
Uta Jappe, H Beckert, Karl‐Christian Bergmann, et al.
Allergologie select (2021) Vol. 5, Iss. 01, pp. 1-25
Open Access | Times Cited: 18
Safety of omalizumab treatment in patients with chronic spontaneous urticaria and COVID‐19
Maria Passante, Maddalena Napolitano, Stefano Dastoli, et al.
Dermatologic Therapy (2021) Vol. 34, Iss. 6
Open Access | Times Cited: 16
Dupilumab efficacy and safety in patients with moderate to severe asthma: A systematic review and meta-analysis
Mohamed Sayed Zaazouee, Asmaa Gomaa Alwarraqi, Yasmine Adel Mohammed, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 12
Real Life Observational Study of Treatment Success of Monoclonal Antibodies for Refractory Chronic Rhinosinusitis with Nasal Polyps
Kathrin Gerstacker, Manuel Christoph Ketterer, Till F. Jakob, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 13, pp. 4374-4374
Open Access | Times Cited: 6
Severe asthma in the era of COVID-19: A narrative review
João Gaspar Marques, Mafalda van Zeller, Pedro Martins, et al.
Pulmonology (2021) Vol. 28, Iss. 1, pp. 34-43
Open Access | Times Cited: 13
Extension of mepolizumab injection intervals as potential of saving costs in well controlled patients with severe eosinophilic asthma
Georg Bölke, Xunliang Tong, Torsten Zuberbier, et al.
World Allergy Organization Journal (2022) Vol. 15, Iss. 10, pp. 100703-100703
Open Access | Times Cited: 9
COVID-19 and Its Impact on Common Diseases in the Allergy Clinics
Emek Kocatürk, Elissa M. Abrams, Marcus Maurer, et al.
The Journal of Allergy and Clinical Immunology In Practice (2023) Vol. 11, Iss. 11, pp. 3289-3303
Closed Access | Times Cited: 5
The Effect of SARS-CoV-2 Virus Infection on the Course of Atopic Dermatitis in Patients
Martyna Miodońska, Agnieszka Bogacz-Piaseczyńska, Magdalena Mróz, et al.
Medicina (2021) Vol. 57, Iss. 6, pp. 521-521
Open Access | Times Cited: 11
Retrospective evaluation of patients with chronic spontaneous urticaria using omalizumab during the COVID‐19 pandemic
Sema Koç Yıldırım, Neslihan Demirel Öğüt, Ece Erbağcı
Journal of Cosmetic Dermatology (2022) Vol. 21, Iss. 2, pp. 431-434
Open Access | Times Cited: 7
Answers to burning questions for clinical allergologists related to the new COVID-19 vaccines
Sabine Altrichter, Stefan Wöhrl, F. Horåk, et al.
Allergo Journal International (2021) Vol. 30, Iss. 5, pp. 169-175
Open Access | Times Cited: 8
Successful Treatment of Atopic Dermatitis with a Predominant Nipple Involvement by Abrocitinib During COVID-19 Pandemic: A Case Report
Yan Teng, Hui Tang, Yong Yu, et al.
Journal of Asthma and Allergy (2023) Vol. Volume 16, pp. 789-792
Open Access | Times Cited: 3
The course of COVID-19 in patients with chronic spontaneous urticaria receiving omalizumab treatment
Emel Atayık, Gökhan Aytekіn
Revue française d'allergologie (2022) Vol. 62, Iss. 8, pp. 684-688
Open Access | Times Cited: 5
Administration of benralizumab in a patient with severe asthma admitted to the intensive care unit with COVID-19 pneumonia: case report
Johannes A. Kroes, Sander Wilhelm Zielhuis, Carina Bethlehem, et al.
European Journal of Hospital Pharmacy (2021) Vol. 29, Iss. 4, pp. 235-236
Open Access | Times Cited: 7
The course of COVID-19 in patients with severe asthma receiving biological treatment
Gülseren Tuncay, Mehmet Erdem Çakmak, Özge Can Bostan, et al.
Journal of Asthma (2021) Vol. 59, Iss. 11, pp. 2174-2180
Closed Access | Times Cited: 7
The effect of COVID-19 on patients recieving omalizumab treatment
Nurhan SAYACA, Kübra Aşık Cansız, Eylem Yıldırım, et al.
Revue française d'allergologie (2023) Vol. 63, Iss. 2, pp. 103281-103281
Open Access | Times Cited: 2
Can we safely use systemic treatment in atopic dermatitis during the COVID-19 pandemic? Overview of selected conventional and biologic systemic therapies
Monika Marko, Rafał Pawliczak
Expert Review of Clinical Immunology (2021) Vol. 17, Iss. 6, pp. 619-627
Closed Access | Times Cited: 5
Perception of the coronavirus pandemic by patients with atopic dermatitis – Results from the TREATgermany registry
Claudia Helmert, Doreen Siegels, Eva Haufe, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2021) Vol. 20, Iss. 1, pp. 45-57
Closed Access | Times Cited: 5
Inflammation Causes Exacerbation of COVID-19: How about Skin Inflammation?
Mayumi Komine, T.M. Ansary, Md Razib Hossain, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 20, pp. 12260-12260
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top